(Q37863833)

English

Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge

scientific article published on 06 September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Chlamydia trachomatis

0 references

0 references

membrane protein

1 reference

based on heuristic

inferred from title

3

object named as

Rino Rappuoli

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Sukumar Pal

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Ellena M Peterson

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Giulio Ratti

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Luis M de la Maza

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

6 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

766-775

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Prevalence of chlamydial and gonococcal infections among young adults in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

AN UNIDENTIFIED VIRUS WHICH PRODUCES PNEUMONIA AND SYSTEMIC INFECTION IN MICE

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Diversity of Chlamydia trachomatis major outer membrane protein genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Sequence of the gene encoding the major outer membrane protein of the mouse pneumonitis biovar of Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Immunity to murine chlamydial genital infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

New Knowledge of Chlamydiae and the Diseases They Cause

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

based on heuristic

inferred from DOI database lookup

Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.074

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.08.074

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37863833&oldid=1756229478"